Myelodysplastic syndrome and myeloproliferative neoplasms

Rami Komrokji MD and Jamile Shammo MD FASCP FACP review data from key studies in myelodysplastic syndrome and myeloproliferative neoplasms presented at the 2015 American Society of Hematology Meeting.

Share

Program Content

Activities

  • Ruxolitinib + IFN-α2 in MPN
    Danish COMBI Trial: Addition of Ruxolitinib to Interferon-α2 Therapy in Philadelphia-Negative Chronic Myeloproliferative Neoplasms
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen